MedPath

Clinical study on susceptibility and side effect prediction of chemoradiotherapy for esophageal cancer by genetic analysis

Not Applicable
Recruiting
Conditions
Esophageal cancer
Registration Number
JPRN-UMIN000030605
Lead Sponsor
The Jikei university school of medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients receiving transfusions, blood products and hematopoietic factor preparations such as G-CSF within 14 days before registration 2) Cases with infections or diseases requiring systemic administration of antibiotics, antifungal agents 3) Cases with complications as shown below Control poor hypertension, diabetes Severe lung disease (interstitial pneumonia, pulmonary fibrosis, advanced emphysema, etc.) Liver failure Gastrointestinal bleeding that requires treatment 4) Patients with marked electrocardiogram abnormality or cases with clinically problematic heart disease Cases with congestive heart failure, symptomatic coronary artery disease, poorly controlled arrhythmia, a history of myocardial infarction that developed within the last 12 months, etc 5) Cases with psychiatric disorder judged by the investigator or test sharing doctor to have acquired consent or adversely affect test performance Control malfunctioning epileptic seizures, central nervous system disorders, etc. 6) Cases with moderate or more ascites (above the pelvic cavity) or with large pleural effusions 7) Cases with brain metastasis or suspected brain metastasis from clinical symptoms 8) Cases with extensive bone metastases 9) Cases with active duplicated cancers 10) HIV antibody positive cases 11) Patients who received treatment with another study drug within 4 weeks before registration of this study or participate in other clinical trials (incidental study of this study "Esophageal cancer chemical radiation by genetic analysis Clinical research on susceptibility of therapy and prediction of side effects "excluding) 12) Cases judged unsuitable as subjects of the examination by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath